Missing Script · Evidence review
Hair loss can make a private diagnosis feel public. For some people, keeping more hair is about recognizing themselves in the mirror or deciding when to tell others what is happening.
That is a reasonable thing to care about. Scalp cooling deserves a practical discussion before chemotherapy starts, including the possibility that it will not work well enough.
What the randomized trial showed
The 2017 SCALP trial randomized 182 women with stage I–II breast cancer receiving taxane- or anthracycline-based chemotherapy. At its planned interim analysis, 142 were evaluable.
After four cycles, hair preservation occurred in 48 of 95 people using cooling, or 50.5%, versus none of 47 controls. “Preservation” meant less than 50% hair loss without requiring a wig. It did not mean everyone kept all their hair.
The study stopped early after meeting its benefit threshold. Changes in the measured quality-of-life, anxiety/depression and body-image scales were not significantly different between groups. Hair retention is a real outcome; it should not automatically become a promise of broader emotional benefit.
The research protocol used device cooling for 30 minutes before, throughout, and 90 minutes after each infusion. This describes that study, not a universal schedule or instructions for home icing.
What about hair recovery later?
A 2024 randomized trial studied people with stage I–III breast cancer receiving chemotherapy before or after surgery. At six months after chemotherapy, persistent alopecia occurred in 12 of 89 participants using cooling (13.5%) and 26 of 50 controls (52.0%).
The benefit was mainly in hair thickness; density did not show the same improvement. This was an open-label study with a six-month endpoint. Persistent thinning at that time is not automatically permanent baldness, and the findings do not guarantee lifelong protection.
A 2024 systematic review found encouraging preservation rates with taxanes, but emphasized that the research largely involved breast cancer. Ask about the evidence for your exact regimen rather than borrowing one success percentage for every chemotherapy.
The burden and safety deserve equal space
A safety review published November 21, 2025 included 67 studies. Chills, cap heaviness and headache were common; the pooled discontinuation rate was 18%. Estimates varied substantially across studies. Device reports also identified cold injuries related to user error, supporting trained fitting and monitoring.
The 2021 ESMO dermatologic-toxicity guideline recommends scalp cooling for chemotherapy-related alopecia in appropriate patients. It lists contraindications including hematologic cancers and cold-related disorders such as cold agglutinin disease and cryoglobulinemia. The infusion team needs to assess suitability.
Breast cancer safety data have not demonstrated an increased scalp-metastasis risk, but rare events are difficult to rule out completely. That reassurance should not be generalized to every cancer. Cooling does not improve cancer control or justify changing the anticancer regimen.
Questions before the first infusion
- What chance of hair preservation is realistic with my drugs and schedule?
- Is there a reason cooling would be unsuitable for me?
- Who fits and monitors the cap, and how much time and cost does it add?
- What support is available if I stop cooling or still lose hair?
Choosing cooling, a wig, a scarf or none of these should remain a personal choice. Good supportive care makes the options understandable and respects the decision.
Evidence checked October 4, 2026. Educational review; discuss individual treatment, exercise and supplement decisions with your care team.
